Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine inflammatory pain model

Neuropharmacology

Volumn 81, Issue , 2014, Pages 224-230

  Anderson, Wayne B ^a   Gould, Michael J ^a   Torres, Romeo D ^a   Mitchell, Vanessa A ^a   Vaughan, Christopher W ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cannabinoid receptors; Fatty acid amide hydrolase; Inflammation; Monoacylglycerol lipase; Pain

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 NITROPHENYL 4 (3 PHENOXYBENZYL)PIPERAZINE 1 CARBOXYLATE; ANALGESIC AGENT; CANNABINOID; CANNABINOID RECEPTOR ANTAGONIST; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; FATTY ACID AMIDASE INHIBITOR; JZL 195; UNCLASSIFIED DRUG; [3' (AMINOCARBONYL)(1,1' BIPHENYL)3 YL]CYCLOHEXYLCARBAMATE; AMIDASE; BENZAMIDE DERIVATIVE; BENZOXAZINE DERIVATIVE; CARBAMIC ACID DERIVATIVE; CYCLOHEXYL CARBAMIC ACID 3'-CARBAMOYLBIPHENYL-3-YL ESTER; FATTY-ACID AMIDE HYDROLASE; JZL195; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ADULT; ALLODYNIA; ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CATALEPSY; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HYPERALGESIA; INFLAMMATORY PAIN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEDATION; SYSTEMIC THERAPY; ANALYSIS OF VARIANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; EXPERIMENTAL ARTHRITIS; EXPLORATORY BEHAVIOR; MOTOR ACTIVITY; PAIN; PAIN MEASUREMENT; TIME;

AMIDOHYDROLASES; ANALGESICS; ANALYSIS OF VARIANCE; ANIMALS; ARTHRITIS, EXPERIMENTAL; BENZAMIDES; BENZOXAZINES; CARBAMATES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; MALE; MICE; MICE, INBRED C57BL; MORPHOLINES; MOTOR ACTIVITY; NAPHTHALENES; PAIN; PAIN MEASUREMENT; PIPERAZINES; PIPERIDINES; PYRAZOLES; TIME FACTORS;

EID: 84895730714     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.12.018     Document Type: Article

References (30)

1. K. Ahn, D.S. Johnson, M. Mileni, D. Beidler, J.Z. Long, and M.K. McKinney et al. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain Chem. Biol. 16 2009 411 420
2. K. Ahn, S.E. Smith, M.B. Liimatta, D. Beidler, N. Sadagopan, and D.T. Dudley et al. Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain J. Pharmacol. Exp. Ther. 338 2011 114 124
3. L. Booker, S.G. Kinsey, R.A. Abdullah, J.L. Blankman, J.Z. Long, and C. Ezzili et al. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice Br. J. Pharmacol. 165 2012 2485 2496
4. H.B. Bradshaw, and J.M. Walker The expanding field of cannabimimetic and related lipid mediators Br. J. Pharmacol. 144 2005 459 465
5. S.R. Chaplan, F.W. Bach, J.W. Pogrel, J.M. Chung, and T.L. Yaksh Quantitative assessment of tactile allodynia in the rat paw J. Neurosci. Methods 53 1994 55 63
6. J.R. Clapper, G. Moreno-Sanz, R. Russo, A. Guijarro, F. Vacondio, and A. Duranti et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism Nat. Neurosci. 13 2010 1265 1270
7. N. Clayton, F.H. Marshall, C. Bountra, and C.T. O'Shaughnessy CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain Pain 96 2002 253 260
8. F. Comelli, G. Giagnoni, I. Bettoni, M. Colleoni, and B. Costa The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation Br. J. Pharmacol. 152 2007 787 794
9. J. De Vry, D. Denzer, E. Reissmueller, M. Eijckenboom, M. Heil, and H. Meier et al. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1- butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects J. Pharmacol. Exp. Ther. 310 2004 620 632
10. V. Di Marzo, and L. De Petrocellis Why do cannabinoid receptors have more than one endogenous ligand? Philos. Trans. R. Soc. Lond. B Biol. Sci. 367 2012 3216 3228
11. V. Di Marzo, L. De Petrocellis, and T. Bisogno The biosynthesis, fate and pharmacological properties of endocannabinoids Handb. Exp. Pharmacol. 2005 147 185
12. S.J. Elmes, L.A. Winyard, S.J. Medhurst, N.M. Clayton, A.W. Wilson, and D.A. Kendall et al. Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat Pain 118 2005 327 335
13. S. Ghosh, L.E. Wise, Y. Chen, R. Gujjar, A. Mahadevan, and B.F. Cravatt et al. The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model Life Sci. 92 2013 498 505
14. M.N. Hill, C.J. Hillard, F.R. Bambico, S. Patel, B.B. Gorzalka, and G. Gobbi The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants Trends Pharmacol. Sci. 30 2009 484 493
15. J.P. Huggins, T.S. Smart, S. Langman, L. Taylor, and T. Young An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee Pain 153 2012 1837 1846
16. A. Jayamanne, R. Greenwood, V.A. Mitchell, S. Aslan, D. Piomelli, and C.W. Vaughan Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models Br. J. Pharmacol. 147 2006 281 288
17. L.J. Kehl, D.T. Hamamoto, P.W. Wacnik, D.L. Croft, B.D. Norsted, and G.L. Wilcox et al. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain Pain 103 2003 175 186
18. S.G. Kinsey, P.S. Naidu, B.F. Cravatt, D.T. Dudley, and A.H. Lichtman Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice Pharmacol. Biochem. Behav. 99 2011 718 725
19. S.G. Kinsey, S.T. O'Neal, J.Z. Long, B.F. Cravatt, and A.H. Lichtman Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay Pharmacol. Biochem. Behav. 98 2011 21 27
20. J.Z. Long, W. Li, L. Booker, J.J. Burston, S.G. Kinsey, and J.E. Schlosburg et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects Nat. Chem. Biol. 5 2009 37 44
21. J.Z. Long, D.K. Nomura, R.E. Vann, D.M. Walentiny, L. Booker, and X. Jin et al. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo Proc. Natl. Acad. Sci. U.S.A. 106 2009 20270 20275
22. N.H. Morgan, I.M. Stanford, and G.L. Woodhall Functional CB2 type cannabinoid receptors at CNS synapses Neuropharmacology 57 2009 356 368
23. P.S. Naidu, S.G. Kinsey, T.L. Guo, B.F. Cravatt, and A.H. Lichtman Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase J. Pharmacol. Exp. Ther. 334 2010 182 190
24. P. Pacher, S. Batkai, and G. Kunos The endocannabinoid system as an emerging target of pharmacotherapy Pharmacol. Rev. 58 2006 389 462
25. S. Petrosino, and V. Di Marzo FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels Curr. Opin. Investig. Drugs 11 2010 51 62
26. D. Piomelli The molecular logic of endocannabinoid signalling Nat. Rev. Neurosci. 4 2003 873 884
27. B.P. Roques, M.C. Fournie-Zaluski, and M. Wurm Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain Nat. Rev. Drug Discov. 11 2012 292 310
28. F.L. Smith, K. Fujimori, J. Lowe, and S.P. Welch Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats Pharmacol. Biochem. Behav. 60 1998 183 191
29. V.C. Wallace, A.R. Segerdahl, D.M. Lambert, S. Vandevoorde, J. Blackbeard, and T. Pheby et al. The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy Br. J. Pharmacol. 151 2007 1117 1128
30. L.E. Wise, K.A. Long, R.A. Abdullah, J.Z. Long, B.F. Cravatt, and A.H. Lichtman Dual fatty acid amide hydrolase and monoacylglycerol lipase blockade produces THC-like Morris water maze deficits in mice ACS Chem. Neurosci. 3 2012 369 378